Meeting
2021 ASCO Annual Meeting
Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.
Authors
John Paul Diaz
Miami Cancer Institute Baptist Health South Florida, Miami, FL
John Paul Diaz , Wenrui Duan , Eric Schroeder , Zuanel Diaz , Nicholas Lambrou , Troy Antony Gatcliffe , Thomas Morrissey , Miguel Angel Villalona-Calero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04483544
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5597)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5597
Abstract #
TPS5597
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool.
First Author: Lauren S. Prescott
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2023 ASCO Annual Meeting
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.
First Author: Lauren Schaff